Exposure to phthalates, bisphenol A and metals in pregnancy and the association with impaired glucose tolerance and gestational diabetes mellitus: The MIREC study  by Shapiro, G.D. et al.
Environment International 83 (2015) 63–71
Contents lists available at ScienceDirect
Environment International
j ourna l homepage: www.e lsev ie r .com/ locate /env intFull length articleExposure to phthalates, bisphenol A and metals in pregnancy and the
association with impaired glucose tolerance and gestational diabetes
mellitus: The MIREC studyG.D. Shapiro a,b, L. Dodds c,⁎, T.E. Arbuckle d, J. Ashley-Martin c, W. Fraser b,e, M. Fisher d, S. Taback f, E. Keely g,
M.F. Bouchard b, P. Monnier h, R. Dallaire i, AS. Morisset b, A.S. Ettinger j
a Department of Social and Preventive Medicine, Université de Montréal, Montréal, Quebec, Canada
b CHU Sainte-Justine Research Centre, Université de Montréal, Montréal, Quebec, Canada
c Dalhousie University, Halifax, Nova Scotia, Canada
d Health Canada, Ottawa, Ontario, Canada
e Department of Obstetrics and Gynecology, Université de Montréal, Montréal, Quebec, Canada
f University of Manitoba, Winnipeg, Manitoba, Canada
g University of Ottawa, Ottawa, Ontario, Canada
h McGill University, Montréal, Quebec, Canada
i Laval University, Québec City, Quebec, Canada
j Yale University, New Haven, CT, USAAbbreviations:BMI,bodymass index;BPA,bisphenolA;
gestational diabetesmellitus; IGT, impaired glucose tolera
MCPP,mono-3-carboxypropyl phthalate;MEHHP,mono-
monoethyl phthalate;MiBP, mono-isobutylphthalate; M
MOP,mono-n-octylphthalate;NHANES,NationalHealthan
tivated receptor; SG, speciﬁc gravity;UPLC, ultra performa
⁎ Corresponding author at: Perinatal Epidemiology Res
E-mail address: L.Dodds@dal.ca (L. Dodds).
http://dx.doi.org/10.1016/j.envint.2015.05.016
0160-4120/© 2015 The Authors. Published by Elsevier Ltda b s t r a c ta r t i c l e i n f oArticle history:
Received 16 December 2014
Received in revised form 11 May 2015
Accepted 24 May 2015
Available online 20 June 2015
Keywords:
Metals
Phthalates
Gestational diabetes
Cohort study
Pregnancy
Arsenic
Background: Studies from several countries report increases in rates of gestational diabetes mellitus (GDM) over
recent decades. Exposure to environmental chemicals could contribute to this trend.
Objectives: To determine the associations between plasticisers andmetals measured in early pregnancy with im-
paired glucose tolerance (IGT) and GDM in a Canadian pregnancy cohort.
Methods:Women enrolled in theMaternal–Infant Research on Environmental Chemicals (MIREC) Studywere in-
cluded if they had a singleton delivery and did not have pre-existing diabetes. Eleven phthalate metabolites and
total bisphenol A (BPA)weremeasured in ﬁrst-trimester urine samples, and fourmetals (lead, cadmium,mercu-
ry and arsenic) weremeasured in ﬁrst-trimester blood samples. IGT and GDMwere assessed in accordance with
standard guidelines by chart review. Chemical concentrations were grouped by quartiles, and associations with
outcomes were examined using logistic regression with adjustment for maternal age, race, pre-pregnancy BMI,
and education. Restricted cubic spline analysis was performed to help assess linearity and nature of any dose–
response relationships.
Results: Of 2001 women recruited into the MIREC cohort, 1274 met the inclusion criteria and had outcome data
and biomonitoring datameasured for at least one of the chemicalswe examined. Elevated odds of GDMwere ob-
served in the highest quartile of arsenic exposure (OR = 3.7, 95% CI = 1.4–9.6) in the adjusted analyses. A sig-
niﬁcant dose–response relationship was observed in a cubic spline model between arsenic and odds of GDM
(p b 0.01). No statistically signiﬁcant associations were observed between phthalates or BPA or other metals
with IGT or GDM.
Conclusions: Our ﬁndings add to the growing body of evidence supporting the role of maternal arsenic exposure
as a risk factor for gestational diabetes.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
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Studies from Canada, the U.S. and Australia report increases in the
prevalence of gestational diabetes mellitus (GDM) in recent decades
(Davenport et al., 2010; Feig et al., 2014; Galtier, 2010). Although the
causes of increasing rates of GDM are likely multifactorial, exposure to
environmental chemicals may be partly responsible for this trend
(Bezek et al., 2008; Kuo et al., 2013; Thayer et al., 2012). Some epidemi-
ologic research has found associations between environmental
chemicals and GDM (Ettinger et al., 2009; Saldana et al., 2007), but
there have not been enough studies on this issue to drawdeﬁnitive con-
clusions. Roughly 4.5% of pregnant women in Canada experience GDM
(Public Health Agency of Canada, 2011). Another group of pregnant
women exhibits impaired glucose tolerance (IGT), or hyperglycemia,
but not meeting the criteria to warrant a diagnosis of GDM (Canadian
Diabetes Association, 2008).
A number of animal toxicity and some human studies have implicat-
ed endocrine disrupting chemicals (EDCs) in the etiology of obesity and
diabetes (Diamanti-Kandarakis et al., 2010; Legler et al., 2015). Several
epidemiologic studies have found associations between exposure to
bisphenol A (BPA) and diabetes (Sun et al., 2014; Lang et al., 2008;
Melzer et al., 2010; Silver et al., 2011; Shankar and Teppala, 2011).
Phthalates have also been associated with type 2 diabetes (Sun et al.,
2014) and insulin resistance (James-Todd et al., 2012; Lind et al.,
2012; Stahlhut et al., 2007) in human populations. However, there are
limited epidemiologic data assessing the risk of metabolic dysfunction
associated with exposure to endocrine disrupting chemicals during
pregnancy (Ettinger et al., 2009; Robledo et al., 2013).
Metals have been a public health concern for many years because
they can persist in the environment and some heavymetals such as cad-
mium and lead have biological half-lives of more than ten years (Health
Canada, 2010). Metals including arsenic, cadmium, lead and mercury
are thought to have estrogenic activity and, as such, are classiﬁed as
EDCs (Choi et al., 2004; Dyer, 2007; Iavicoli et al., 2009; Watson and
Yager, 2007). In addition to such naturally-occurring EDCs as these
metals, some manufactured chemicals such as phthalates and BPA
may also have endocrine disrupting properties (Caserta et al., 2011;
Diamanti-Kandarakis et al., 2009). Many of the above-mentioned
chemicals are either naturally occurring or are used extensively in ev-
eryday consumer products and are, therefore, ubiquitous in our
environment.
Because of the potential for long-term consequences of GDM in both
mother and offspring, it is important to better characterize the potential
role that environmental chemicals may play in the development of
glucose disorders during pregnancy. Using data from a Canadian birth
cohort, this study sought to determinewhether exposure to phthalates,
BPA or metals, assessed by measurements made in blood and urine,
were associated with increased risk of GDM or IGT during pregnancy.
2. Methods
2.1. Study population
The Maternal–Infant Research on Environmental Chemicals
(MIREC) study is a longitudinal birth cohort study conducted in
Canada. Further details concerning inclusion and exclusion criteria
and study objectives and procedures have been published elsewhere
(Arbuckle et al., 2013). Women at least 18 years of age (n = 2001)
were recruited during the ﬁrst trimester of pregnancy (6 to
b14weeks gestation), between 2008 and 2011 at 10 sites in 6 Canadian
provinces. Contacts during each trimester of pregnancy were made
with each participant to collect questionnaire data, medical history,
andmaternal blood and urine. Detailed clinical informationwas collect-
ed in a post-delivery chart review. The present analysis focused on
MIREC participants with a singleton fetus that resulted in a live birth,
who had sufﬁcient data from a glucose challenge test (GCT) and/ororal glucose tolerance test (OGTT) to determine diagnoses of GDM
and IGT, and for whom a ﬁrst-trimester measurement of phthalates,
BPA and/or metals was available. All participants signed informed con-
sent forms and the study received ethical approval from the IWKHealth
Centre (Halifax, NS), Health Canada, and all the study centers.
Of 2001 women recruited into the MIREC study, 18 withdrew and
asked that all their data and biospecimens be destroyed (0.9%). Of the
remaining 1983 women, a total of 98 were excluded (4.9%) because of
amultiple pregnancy (n=48), stillbirth (n=21), pre-existing diabetes
(n = 24), or having no biological samples available for the measure-
ment of any of the contaminants of interest (n = 5), leaving 1885
who contributed data to the study (Fig. 1).
2.2. Chemical biomonitoring data
Eleven phthalate metabolites and total BPA were measured in ﬁrst-
trimester urine samples, as previously described (Arbuckle et al., 2014),
and four metals (lead, cadmium, mercury and arsenic) were measured
from ﬁrst-trimester blood samples. Phthalate metabolites included
monoethyl phthalate (MEP), mono-n-butyl phthalate (MBP), mono-
benzyl phthalate (MBzP), mono-3-carboxypropyl phthalate (MCPP),
monoethylhexyl phthalate (MEHP), mono-(2-ethyl-5-hydroxyhexyl)
phthalate (MEHHP), mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP),
monocyclohexyl phthalate (MCHP), mono-n-octyl phthalate (MOP),
mono-isononyl phthalate (MNP) and monomethyl phthalate (MMP).
All chemical analyses of urine and blood samples were carried out at
the Toxicology Centre of the Quebec Institute of Public Health (Institut
national de santé publique du Québec), accredited by the Standards
Council of Canada. Phthalates in urine were analyzed by LC–MS/MS
with an Ultra Performance Liquid Chromatography (UPLC) coupled
with a tandem mass spectrometer and Quattro Premier XE following
enzymatic deconjugation, as described in detail elsewhere (Arbuckle
et al., 2014; Langlois et al., 2014). Total BPA in urine was measured
with a GC–MS–MS instrument with a GC Agilent 6890 N (Agilent Tech-
nologies; Mississauga, Ontario, Canada) coupled with a tandem mass
spectrometer Quattro Micro GC (Waters; Milford, Massachusetts,
USA). An enzymatic hydrolysis freed the conjugated compounds in
the urine, the samples were then derivatized and the derivatives ex-
tracted and analyzed. Metals were measured in whole blood using in-
ductively coupled plasma mass spectrometry (PerkinElmer ELAN ICP-
MS DRC II).
Concentrations below the limit of detection (LOD) were substituted
as one half the LOD. Due to the exploratory nature of our study, we ex-
amined each chemical separately for the principal analyses. However,
three of the phthalates metabolites are primary (MEHP) and secondary
(MEHHP, MEOHP) metabolites of the parent compound di(2-
ethylhexyl) phthalate (DEHP) (Hauser and Calafat, 2005). Considering
the high correlation (≥0.85) between these metabolites, these were
not analyzed as individual metabolites, but summed to create an
index of DEHP exposure, as has been previously carried out (Hoppin
et al., 2013). Four of the phthalate metabolites (MCHP, MOP, MNP and
MMP) had a high degree of non-detect (more than 75%) in the urine
and were not examined further in the present analyses.
2.3. Impaired glucose tolerance and gestational diabetes mellitus
IGT andGDMwere assessed by chart review based on the results of a
50 g glucose challenge test (GCT) and 75 or 100 g oral glucose tolerance
test (OGTT), in accordance with guidelines from the Canadian Diabetes
Association and the Society of Obstetricians and Gynaecologists of
Canada (Berger et al., 2002; Canadian Diabetes Association, 2008).
These guidelines specify cut-off values of 5.3mmol/L for fasting glucose,
10.6 mmol/L 1 hour post glucose, and 8.9 mmol/L 2 hour post glucose
for a 75-g OGTT. Cut-off values for a 100-g OGTT are 5.8 mmol/L for
fasting glucose, 10.6 mmol/L 1 hour post glucose, 9.2 mmol/L 2 hour
post glucose, and 8.0 mmol/L 3 hour post glucose. Subjects were
Fig. 1. Study participants and outcome classiﬁcation.
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exceeded. If the result of the 1-hour 50 g GCTwas ≥10.3 mmol/L, or if at
least 2 of the cut-off values were met or exceeded on a 75 g or 100 g
OGTT, a diagnosis of GDMwas assigned.
Some of the MIREC study centers screened only high-risk patients
for GDM. Of the 1885 subjects meeting inclusion criteria and having ex-
posure data, 575 had no information from a GCT or OGTT, and a further
36had a GCT result between 7.8 and 10.2mmol/L but no information on
an OGTT (Fig. 1). In accordance with the guidelines, we could not make
a determination of GDMor IGT for 611women, leaving 1274women for
our principal analyses.
2.4. Statistical analyses
Descriptive statistics for maternal demographic and clinical charac-
teristics were calculated according to study outcomes (normal blood
glucose, IGT, GDM) using frequency distributions and chi-square tests
of signiﬁcance. Geometric means and standard deviations were calcu-
lated for chemical concentrations according to study outcomes. In
determining the geometric mean, concentrations of phthalate metabo-
lites and BPA were adjusted for urinary speciﬁc gravity (SG) according
to the following formula: Pc = Pi [(SGm − 1) / (SGi − 1)], where
Pc= SG-adjustedmetabolite concentration (μg/mL), Pi = observedme-
tabolite concentration, SGi = speciﬁc gravity of the urine sample, and
SGm =median SG for the cohort (Just et al., 2010).
All blood and urine contaminant concentrations were grouped into
quartiles for analyses, and logistic regression models were used to ex-
amine associations between quartiles and study outcomes. In calculat-
ing odds ratios for these outcomes, we examined subjects with GDM
vs. normal blood glucose, IGT vs. normal glucose, and subjects witheither IGT or GDM grouped together vs. normal blood glucose. We ex-
amined the following maternal variables as potential confounders: age
at delivery (≤29, 30–34, ≥35), pre-pregnancy BMI (b25, 25–29.9,
≥30 kg/m2), parity (nulliparous vs. parous), household income
($ ≤ 30,000, 30,001–50,000, 50,001–100,000, N100,000), education
(high school diploma or less, some college or trade school, undergradu-
ate university degree, graduate university degree), race (White, non-
White), and smoking (never or quit before pregnancy, quit when
knewpregnant, current smoker). Variables were selected a priori for in-
clusion in multivariable models on the basis of associationwith IGT and
GDM in univariable analyses (p b 0.1) or on the basis of evidence of an
association from the literature. As model results were not substantially
different with adjustment for both income and education vs. adjust-
ment for education only, we did not adjust for income in the ﬁnal
models. Speciﬁc gravity was included as a covariate in all adjusted
models for chemicals measured in urine to account for heterogeneity
in urinary dilution. For models with statistically signiﬁcant association
estimates, we used restricted cubic spline analysis to further examine
the dose–response relationship (Desquilbet and Mariotti, 2010). This
technique is applicable when there is no a priori hypothesis regarding
the shape of the dose–response association, and it overcomes the inher-
ent limitations of the categorical analyses. Knots were set at the 5th,
50th, and 95th percentiles and the referent value was set to themedian.
3. Results
Table 1 shows the maternal characteristics of the study population
and the distribution of IGT and GDM cases with respect to these charac-
teristics. Less than 5% of study subjects smoked during pregnancy, and
more than a third of the study population was overweight or obese.
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(4.6%) were identiﬁed as having IGT. As expected, rates of GDM and
IGT were higher among overweight and obese women than among
women with normal or low pre-pregnancy BMI. A total of 611 partici-
pants were excluded from analyses due to insufﬁcient outcome data
(Fig. 1). This group included a lower proportion of women who were
obese (10.3% vs. 15.0% of included participants, p = .05) and a higher
proportion of Caucasian women (88.1% vs. 84.5%, p = .04). Excluded
participants were also more frequently current smokers (7.5% vs. 4.4%,
p = .04).
Table 2 shows the percentage of samples below the LOD and the
geometric mean for each chemical analyzed, stratiﬁed by the three out-
come categories (normal blood glucose, IGT, GDM). The Pearson corre-
lation coefﬁcients between the various phthalates and BPA were all
statistically signiﬁcant (p b .01) and ranged from 0.30 (between MEP
and BPA) to 0.71 (between MBP and MBzP). For metals, correlations
ranged from−0.04 (between cadmium and arsenic) to 0.34 (between
mercury and arsenic). The correlations between cadmium andmercury
and between cadmium and arsenic were not statistically signiﬁcant
(p N .13), while correlations between all other metals were statistically
signiﬁcant (p b .01).
Table 3 shows the crude and adjusted odds of each individual out-
come (GDM vs. normal glucose; IGT vs. normal glucose) and for the
two outcomes of interest combined (IGT or GDM vs. normal glucose)
by quartile of phthalates and BPA urinary concentrations. In comparing
odds of GDM in the upper three quartiles vs. the lowest quartile for
phthalates and BPA, no statistically signiﬁcant associations were ob-
served in the adjusted models. Increased odds of IGT were observed
for the third and fourth quartiles of MBzP in unadjusted analyses
(third quartile: OR = 2.8, 95% CI = 1.0–7.8; fourth quartile: OR = 2.8,
95% CI = 1.0–8.0). After adjusting for confounders, point estimates
were similar to the crude analyses but the conﬁdence interval no longer
excluded the null effect (third quartile: OR = 2.9, 95% CI = 0.9–9.4;
fourth quartile: OR = 2.9, 95% CI = 0.9–10.4). A similar pattern but
with attenuated odds ratios was observed for the combined GDM/IGT
outcome (adjustedOR for third quartile=2.0, 95%CI=0.9–4.4; adjust-
ed OR for fourth quartile = 2.0, 95% CI = 0.9–4.8).Table 1
Study population characteristics by glycemic status (N= 1274).
Total subjects (%)
N 1274
Age ≤29 308 (24.2)
30–34 447 (35.1)
≥35 515 (40.4)
Missing 4 (0.3)
Pre-pregnancy BMI (kg/m2) Underweight or normal (b25) 752 (59.0)
Overweight (25–29.9) 257 (20.2)
Obese (≥30) 191 (15.0)
Missing 74 (5.8)
Parity Nulliparous 563 (44.2)
Parous 709 (55.7)
Missing 2 (0.2)
Education High school diploma or less 106 (8.3)
Some college, or trade school 352 (27.6)
Undergraduate university degree 477 (37.4)
Graduate university degree 338 (26.5)
Missing 1 (0.1)
Household Income ($CAD) ≤50,000 209 (16.4)
50,001–100,000 505 (39.6)
≥100,000 506 (39.7)
Missing 54 (4.2)
Race White 1077 (84.5)
Non-White 197 (15.5)
Smoking Never or quit before pregnancy 1124 (88.2)
Quit when knew pregnant 93 (7.3)
Current smoker 56 (4.4)
Missing 1 (0.1)
Percentages shown in the Total subjects column reﬂect the entire study population, while thos
a vs. normal glucose.In comparing the odds of GDM in the upper three quartiles vs. the
lowest quartile for metals (Table 4), elevated odds of GDM were ob-
served in the highest quartile of arsenic (adjusted OR = 3.7, 95% CI =
1.4–9.6). In the cubic splinemodels, there was a signiﬁcant relationship
between arsenic level and odds of GDM (p b .01) (Fig. 2). A test of the
null hypothesis that the effect of arsenic level and odds of GDM is linear
was not rejected (p = .92), suggesting a linear association.
Elevated odds of combined GDM/IGT were also observed for the
highest quartile of arsenic (adjusted OR = 1.9, 95% CI = 1.1–3.5).
Cubic spline analysis showed a statistically signiﬁcant relationship be-
tween arsenic and odds of GDM/IGT combined (p = 0.03) (Fig. 3),
while a test of the null hypothesis of linearity was not rejected (p =
.09). Elevated odds of GDMwere observed in the highest quartile of cad-
mium in unadjusted analyses (OR=2.9, 95% CI= 1.2–7.0) but after ad-
justment, the conﬁdence interval included the null effect. (OR = 2.5,
95% CI = 1.0–6.4). No statistical evidence of associations with GDM or
IGT was observed for the other metals.
4. Discussion
In this longitudinal birth cohort study of Canadian women, we eval-
uated the association between maternal concentrations of phthalates,
BPA and metals with IGT and GDM. After adjustment for confounding
variables, we observed statistical evidence of relationships between
blood arsenic concentration with GDM and GDM or IGT combined, but
not IGT alone. We found no statistical evidence of a relationship be-
tween levels of the other chemicalswe examined andGDMor IGT in ad-
justed analyses.
While statistical evidence of an association between arsenic expo-
sure and GDM was found only for the top quartile in regression analy-
ses, the spline curve suggested a linear relationship with no evidence
of a threshold. Two previous studies, a U.S. based cohort study
(Ettinger et al., 2009) and a Chinese case–control study (Peng et al.,
2015), both found signiﬁcant associations between arsenic exposure
and gestational diabetes. Other studies have examined arsenic exposure
in relation to type 2 diabetes. Two cross-sectional analyses from the U.S.
National Health and Nutrition Examination Survey (NHANES) showedNormal glucose (%) IGT cases (%) p-Value a GDM cases (%) p-Value a
1167 59 48
289 (93.8) 13 (4.2) 0.26 6 (1.9) 0.20
406 (90.8) 19 (4.3) 22 (4.9)
469 (91.1) 26 (5.0) 20 (3.9)
3 (75.0) 1 (25.0) 0 (0.0)
713 (94.8) 20 (2.7) b .01 19 (2.5) 0.02
230 (89.5) 14 (5.4) 13 (5.1)
163 (85.3) 16 (8.4) 12 (6.3)
61 (82.4) 9 (12.2) 4 (5.4)
518 (92.0) 22 (3.9) 0.53 23 (4.1) 0.86
647 (91.3) 37 (5.2) 25 (3.5)
2 (100.0) 0 (0.0) 0 (0.0)
99 (93.4) 1 (0.9) b .01 6 (5.7) 0.74
304 (86.4) 33 (9.4) 15 (4.3)
446 (93.5) 15 (3.1) 16 (3.4)
317 (93.8) 10 (3.0) 11 (3.3)
1 (100.0) 0 (0.0) 0 (0.0)
185 (88.5) 13 (6.2) 0.20 11 (5.3) 0.47
458 (90.7) 27 (5.3) 20 (4.0)
475 (93.9) 16 (3.2) 15 (3.0)
49 (90.7) 3 (5.6) 2 (3.7)
997 (92.6) 50 (4.6) 0.88 30 (2.8) b .01
170 (86.3) 9 (4.6) 18 (9.1)
1035 (92.1) 50 (4.4) 0.19 39 (3.5) 0.42
79 (84.9) 8 (8.6) 6 (6.5)
52 (92.9) 1 (1.8) 3 (5.4)
1 (100.0) 0 (0.0) 0 (0.0)
e for the three outcome groups reﬂect each population stratum.
Table 2
Geometric mean (SD) concentrations of urinary phthalate metabolites and bisphenol A (BPA) and blood metals in ﬁrst trimester pregnancy specimens by glycemic status.
Chemical concentration (μg/L) a, b LOD % b LOD Geometric mean (SD)
Total
N c
Normal glucose
N = 1167
IGT cases
N = 59
GDM cases
N = 48
Monoethyl phthalate (MEP) 0.50 0.1 1152 38.8 (4.1) 34.5 (2.9) 34.5 (4.0)
Mono-n-butylphthalate (MBP) 0.20 0.1 1152 13.3 (2.2) 12.6 (2.4) 12.3 (1.9)
Mono-benzyl phthalate (MBzP) 0.20 0.7 1152 5.8 (2.7) 5.9 (2.8) 6.3 (2.9)
Mono-3-carboxypropyl phthalate (MCPP) 0.20 16.0 1152 1.0 (3.0) 0.9 (2.8) 0.8 (3.2)
Monoethylhexyl phthalate (MEHP) 0.20 1.7 1143 2.6 (2.5) 2.3 (2.4) 2.7 (2.9)
Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) 0.40 0.6 1152 10.6 (2.5) 10.4 (2.4) 11.4 (3.0)
Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) 0.20 0.2 1152 7.4 (2.3) 6.9 (2.2) 7.8 (2.7)
Bisphenol A (BPA) 0.20 12.7 1247 0.9 (2.7) 0.9 (2.6) 0.9 (2.7)
Lead (μg/dL) 0.10 0.0 1259 0.6 (1.6) 0.6 (1.7) 0.6 (1.7)
Cadmium 0.04 2.9 1259 0.2 (2.2) 0.2 (2.5) 0.3 (2.4)
Mercury 0.10, 0.12 9.3 1259 0.6 (3.0) 0.5 (3.3) 0.9 (3.0)
Arsenic 0.22 6.1 1259 0.8 (2.2) 0.7 (2.5) 1.1 (2.1)
a Geometric mean concentrations for phthalate metabolites and BPA are adjusted for speciﬁc gravity (Just et al., 2010).
b The following phthalate metabolites had more than 75% of non-detect and were not further examined: Monocyclohexyl phthalate (MCHP), mono-n-octyl phthalate (MOP), mono-
isononyl phthalate (MNP), monomethyl phthalate (MMP).
c Number of subjects with data for at least one exposure measurement.
67G.D. Shapiro et al. / Environment International 83 (2015) 63–71strong associations between total arsenic and diabetes prevalence
(Navas-Acien et al., 2008, 2009). Several mechanisms have been pro-
posed to support the associations between arsenic and diabetes. Arsenic
is hypothesized to increase the risk of diabetes through oxidative stress,
upregulation of inﬂammatorymarkers (tumor necrosis factor alpha and
interleukin 6), and inhibition of peroxisome proliferator-activated
receptor-γ (PPAR-γ) (Tseng, 2004). Experimental studies have shown
inorganic arsenic to impair insulin-dependent glucose uptake andTable 3
Odds ratios (95% CI) for GDM, IGT, and GDM or IGT by quartiles of phthalate metabolites and b
Chemical (μg/L) GDM (N = 43) vs. normal
glucose (N = 1080) a
Unadjusted
OR (95% CI)
Adjusted OR b
(95% CI)
MEP Q1 (0.3–11.0) 1 1
Q2 (12.0–28.0) 0.7 (0.3–1.8) 0.7 (0.3–1.8)
Q3 (29.0–90.0) 1.0 (0.5–2.4) 0.8 (0.3–2.1)
Q4 (91.0–6600.0) 0.8 (0.3–2.0) 0.5 (0.2–1.4)
p-Value c 0.25
MBP Q1 (0.1–5.0) 1 1
Q2 (5.1–11.0) 1.7 (0.7–4.2) 1.7 (0.6–4.4)
Q3 (12.0–24.0) 1.5 (0.6–3.7) 1.0 (0.3–3.2)
Q4 (25.0–1500.0) 1.2 (0.4–3.1) 0.6 (0.1–2.2)
p-Value c 0.29
MBzP Q1 (0.1–2.1) 1 1
Q2 (2.2–4.8) 0.7 (0.2–1.9) 0.7 (0.2–2.2)
Q3 (4.9–12.0) 1.5 (0.7–3.6) 1.5 (0.6–4.2)
Q4 (13.0–420.0) 1.5 (0.6–3.7) 1.5 (0.5–4.7)
p-Value c 0.28
MCPP Q1 (0.1–0.3) 1 1
Q2 (0.3–0.9) 1.3 (0.6–3.1) 1.2 (0.5–2.9)
Q3 (0.9–2.0) 0.9 (0.4–2.2) 0.6 (0.2–1.8)
Q4 (2.1–100.0) 1.1 (0.4–2.7) 0.6 (0.2–1.9)
p-Value c 0.27
∑ DEHP Q1 (0.4–8.0) 1 1
Q2 (8.0–17.4) 1.1 (0.5–2.7) 1.0 (0.4–2.5)
Q3 (17.5–36.5) 0.6 (0.2–1.7) 0.4 (0.1–1.5)
Q4 (36.8–2470.0) 1.5 (0.7–3.5) 0.9 (0.3–2.9)
p-Value c 0.72
BPA Q1 (0.1–0.4) 1 1
Q2 (0.4–0.8) 1.9 (0.8–4.7) 1.8 (0.7–4.5)
Q3 (0.8–1.6) 1.6 (0.6–4.0) 1.5 (0.5–4.5)
Q4 (1.7–95.0) 1.2 (0.5–3.2) 1.1 (0.3–3.6)
p-Value c 0.99
a Number of subjects with data for at least one exposure measurement and all covariates.
b Adjusted for maternal age, race, pre-pregnancy BMI, education and speciﬁc gravity.
c p-Value from linear test across exposure categories.glucose-stimulated insulin secretion (Huang et al., 2011). Arsenic may
also increase diabetes risk through endocrine-disrupting mechanisms
(Davey et al., 2007) and by altering methylation patterns of diabetes-
related genes (Smeester et al., 2011).
Despite some studies suggesting a positive association between ar-
senic exposure and development of diabetes and proposedmechanisms
to support associations, several literature reviews have emphasized the
inconclusive nature of overall evidence (Huang et al., 2011;Navas-Acienisphenol A in ﬁrst trimester urine.
IGT (N = 47) vs. normal
glucose (N = 1080) a
GDM or IGT (N = 90) vs.
normal glucose (N = 1080) a
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
Unadjusted
OR (95% CI)
Adjusted
OR (95% CI)
1 1 1 1
1.6 (0.7–3.7) 1.5 (0.6–3.8) 1.1 (0.6–2.0) 1.0 (0.5–2.0)
1.0 (0.4–2.7) 0.8 (0.3–2.4) 1.0 (0.6–2.0) 0.8 (0.4–1.7)
1.3 (0.5–3.2) 1.0 (0.4–3.0) 1.0 (0.5–1.9) 0.7 (0.3–1.5)
0.72 0.29
1 1 1 1
1.8 (0.7–4.7) 1.9 (0.7–5.2) 1.8 (0.9–3.4) 1.8 (0.9–3.6)
1.8 (0.7–4.7) 1.7 (0.5–5.4) 1.6 (0.8–3.2) 1.3 (0.6–3.0)
1.6 (0.6–4.3) 1.2 (0.3–4.6) 1.4 (0.7–2.8) 0.8 (0.3–2.2)
0.95 0.51
1 1 1 1
2.2 (0.8–6.5) 2.3 (0.8–7.2) 1.2 (0.6–2.6) 1.3 (0.6–2.8)
2.8 (1.0–7.8) 2.9 (0.9–9.4) 2.0 (1.0–3.8) 2.0 (0.9–4.4)
2.8 (1.0–8.0) 2.9 (0.8–10.4) 2.0 (1.0–3.9) 2.0 (0.9–4.8)
0.13 0.07
1 1 1 1
1.8 (0.7–4.4) 1.8 (0.7–4.5) 1.5 (0.8–2.9) 1.5 (0.7–2.8)
0.6 (0.2–1.9) 0.5 (0.1–1.8) 0.8 (0.4–1.6) 0.6 (0.2–1.3)
2.2 (0.9–5.2) 1.6 (0.5–4.8) 1.6 (0.8–3.0) 1.0 (0.4–2.3)
0.70 0.63
1 1 1 1
1.3 (0.5–3.1) 1.1 (0.4–2.8) 1.2 (0.6–2.3) 1.0 (0.5–2.0)
1.1 (0.5–2.8) 0.9 (0.3–2.7) 0.9 (0.4–1.7) 0.6 (0.3–1.5)
1.4 (0.6–3.5) 1.0 (0.3–3.4) 1.5 (0.8–2.7) 0.9 (0.4–2.3)
0.91 0.75
1 1 1 1
1.4 (0.6–3.3) 1.2 (0.5–2.9) 1.6 (0.9–3.1) 1.5 (0.8–2.9)
0.7 (0.3–2.0) 0.6 (0.2–1.7) 1.1 (0.6–2.2) 0.9 (0.4–2.0)
1.8 (0.8–4.1) 1.3 (0.5–3.6) 1.6 (0.8–2.9) 1.2 (0.5–2.7)
0.79 0.92
Table 4
Odds ratios (95% CI) for GDM, IGT, and GDM or IGT by quartiles of metals in ﬁrst trimester blood.
GDM (N = 44) vs. normal
glucose (N = 1088) a
IGT (N = 49) vs. normal
glucose (N = 1088) a
GDM or IGT (N = 93) vs.
normal glucose (N = 1088) a
Metal Unadjusted
OR (95% CI)
Adjusted OR b
(95% CI)
Unadjusted
OR (95% CI)
Adjusted OR b
(95% CI)
Unadjusted
OR (95% CI)
Adjusted
OR b (95% CI)
Lead (μg/dL) Q1 (0.2–0.4) 1 1 1 1 1 1
Q2 (0.5–0.6) 0.8 (0.3–1.8) 0.8 (0.3–1.9) 0.7 (0.3–1.5) 0.8 (0.4–1.8) 0.7 (0.4–1.3) 0.8 (0.4–1.5)
Q3 (0.6–0.9) 0.6 (0.2–1.4) 0.6 (0.2–1.6) 0.4 (0.2–1.0) 0.6 (0.2–1.3) 0.5 (0.3–0.9) 0.6 (0.3–1.1)
Q4 (0.9–4.1) 1.1 (0.5–2.3) 1.1 (0.5–2.6) 0.7 (0.3–1.6) 0.9 (0.4–2.1) 0.9 (0.5–1.5) 1.0 (0.6–1.8)
p-Value c 0.87 0.62 0.76
Cadmium (μg/L) Q1 (0.0–0.1) 1 1 1 1 1 1
Q2 (0.2–0.2) 2.1 (0.8–5.4) 2.1 (0.8–5.4) 0.8 (0.4–1.9) 0.9 (0.4–2.1) 1.3 (0.7–2.3) 1.3 (0.7–2.4)
Q3 (0.2–0.3) 1.3 (0.5–3.7) 1.4 (0.5–3.9) 0.8 (0.3–1.8) 0.8 (0.3–1.8) 1.0 (0.5–1.8) 1.0 (0.5–1.8)
Q4 (0.3–5.1) 2.9 (1.2–7.0) 2.5 (1.0–6.4) 1.1 (0.5–2.3) 1.0 (0.5–2.3) 1.6 (0.9–2.9) 1.5 (0.8–2.7)
p-Value c 0.13 0.95 0.38
Mercury (μg/L) Q1 (0.1–0.3) 1 1 1 1 1 1
Q2 (0.4–0.7) 1.2 (0.5–3.2) 1.1 (0.4–2.9) 1.2 (0.5–2.5) 1.1 (0.5–2.3) 1.2 (0.6–2.2) 1.1 (0.6–2.1)
Q3 (0.7–1.4) 1.7 (0.7–4.2) 1.4 (0.6–3.7) 0.8 (0.4–1.9) 0.9 (0.4–2.1) 1.2 (0.6–2.2) 1.1 (0.6–2.1)
Q4 (1.4–10.0) 1.8 (0.8–4.5) 1.7 (0.7–4.5) 1.0 (0.4–2.2) 1.2 (0.5–2.7) 1.3 (0.7–2.4) 1.4 (0.7–2.7)
p-Value c 0.21 0.88 0.34
Arsenic (μg/L) Q1 (0.1–0.5) 1 1 1 1 1 1
Q2 (0.5–0.8) 0.7 (0.2–2.5) 0.7 (0.2–2.3) 0.8 (0.4–1.8) 0.8 (0.4–1.8) 0.8 (0.4–1.6) 0.8 (0.4–1.5)
Q3 (0.9–1.2) 2.5 (0.9–6.7) 2.5 (0.9–6.9) 0.7 (0.3–1.7) 0.8 (0.3–1.9) 1.3 (0.7–2.4) 1.3 (0.7–2.5)
Q4 (1.3–34.5) 3.8 (1.5–9.5) 3.7 (1.4–9.6) 1.0 (0.5–2.3) 1.2 (0.5–2.6) 1.9 (1.0–3.3) 1.9 (1.1–3.5)
p-Value c b .01 0.76 0.01
a Number of subjects with data for at least one exposure measurement and all covariates.
b Adjusted for maternal age, race, pre-pregnancy BMI, and education.
c p-Value from linear test across exposure categories.
68 G.D. Shapiro et al. / Environment International 83 (2015) 63–71et al., 2006; Andra et al., 2013). A 2011 U.S. National Toxicological Pro-
gramworkshop concluded that epidemiological evidencewas inconclu-
sive at lower exposure levels and did not reach the threshold for a
‘sufﬁcient’ classiﬁcation at high arsenic exposure levels (Maull et al.,
2012). A later updated systematic review reached a similar conclusion
(Kuo et al., 2013).
Although several epidemiologic studies have investigated the rela-
tionship between BPA exposure and type 2 diabetes, only one small
pilot study has looked at BPA exposure andGDMand found no evidence
of an association (Robledo et al., 2013). Analysis from nested case–con-
trol studies found signiﬁcant associations between urinary BPA and in-
cident type 2 diabetes within the Nurses' Health Study II (NHSII) but
not the NHS (Sun et al., 2014). The different ﬁnding between these co-
horts may be explained by the age differences of participants at the
time of sample collection; stronger effects were observed in younger
women. Moderate associations were found between urinary BPA andFig. 2. Restricted spline curve association between log10 arsenic (μg/L) and odds of GDM,
adjusted for maternal age, race, pre-pregnancy BMI and education. Knots were located at
the 5th, 50th and 95th percentiles. Dashed lines = 95% CI; dots = knots.self-reported diabetes in the 2003–2004 wave of NHANES (Lang et al.,
2008) as well as in a pooled analysis from 2003–2006 (Melzer et al.,
2010). In larger pooled analyses from 2003–2008, signiﬁcant associa-
tions were found between BPA levels and diabetes prevalence as
assessed by hemoglobin A1c and self-report (Silver et al., 2011),
laboratory-diagnosed prediabetes (Sabanayagam et al., 2013), and dia-
betes (Shankar and Teppala, 2011). Despite this body of literature, two
recent systematic reviews examined the relationship between BPA ex-
posure and type 2 diabetes and concluded that there is insufﬁcient evi-
dence to conﬁrm a causal link between BPA exposure and type 2
diabetes (Kuo et al., 2013; LaKind et al., 2014).
A number of experimental studies have demonstrated potential
mechanisms underlying the association between BPA exposure and
diabetes. BPA has been associated with altered β-cell function
(Diamanti-Kandarakis et al., 2009; Kuo et al., 2013; Alonso-Magdalena
et al., 2006; Soriano et al., 2012), adiponectin release (Diamanti-Fig. 3. Restricted spline curve association between log10 arsenic (μg/L) and odds of GDM
or IGT, adjusted for maternal age, race, pre-pregnancy BMI and education. Knots were
located at the 5th, 50th and 95th percentiles. Dashed lines = 95% CI; dots = knots.
69G.D. Shapiro et al. / Environment International 83 (2015) 63–71Kandarakis et al., 2009; Kuo et al., 2013; Hugo et al., 2008), insulin re-
lease (Soriano et al., 2012) and insulin levels (Alonso-Magdalena et al.,
2006). Gestational BPA exposure was associated with insulin resistance
and glucose tolerance in mice (Alonso-Magdalena et al., 2010). More-
over, BPA has been shown to be associated with altered insulin release
in human tissue samples (Soriano et al., 2012).
Positive associations between phthalates and type 2 diabetes were
found in the NHSII (Sun et al., 2014) and NHANES (James-Todd et al.,
2012) cohorts, as well as in cross-sectional studies from Mexico
(Svensson et al., 2011) and Sweden (Lind et al., 2012). Biological evi-
dence supports a possible role for phthalates in the development of di-
abetes, principally through activation of PPARs, which in turn affect
adipogenesis, lipid storage and the control of insulin sensitivity
(Casals-Casas and Desvergne, 2011; Hurst and Waxman, 2003).
There is some biological evidence linking diabetes withmetals other
than arsenic. Cadmium (Kawakami et al., 2010; Kuo et al., 2013) and
mercury (Chen et al., 2006; Kuo et al., 2013) are hypothesized to in-
crease diabetes risk through impacts on pancreatic β-cell function and
adiponectin release. Our negative ﬁndings regarding lead, cadmium
and mercury are consistent with most existing literature examining
these exposures in relation to diabetes. It should be noted that most of
these studies were not conducted in pregnant women. A 2003 cross-
sectional study using data from the U.S. NHANES III found a positive as-
sociation between urinary cadmium and both diabetes and impaired
fasting glucose (Schwartz et al., 2003). However, subsequent studies
(Barregard et al., 2013;Moon, 2013; Swaddiwudhipong et al., 2010), in-
cluding those measuring cadmium in blood (Barregard et al., 2013;
Moon, 2013), have failed to conﬁrm this ﬁnding (Kuo et al., 2013).
One long-term prospective study found an association between toenail
mercury and diabetes (He et al., 2013), but research to date onmercury
and diabetes is limited and themajority of studies have not found a sig-
niﬁcant association (Moon, 2013;Mozaffarian et al., 2013). The Chinese
case–control study, in which metals were measured in meconium, re-
ported signiﬁcant dose–response trends across exposure quartiles of
mercury and cadmium. The third and fourth quartiles of cadmiumexpo-
surewere associatedwith a signiﬁcantly increased risk of gestational di-
abetes. Interestingly, they found signiﬁcantly reduced odds ratios for
the second and third quartile of lead compared to the ﬁrst quartile
(Peng et al., 2015).
In light of the varied ﬁndings in the literature, it is not clear whether
the lack of association for BPA, phthalates and most metals observed in
our study reﬂects true null ﬁndings, or possibly rather is a function of
the low overall exposure levels or other unmeasured characteristics of
the MIREC study population. Urinary concentrations of phthalates and
BPA observed in the MIREC study are substantially lower than those
found in several other pregnancy cohorts (Casas et al., 2011; Engel
et al., 2009; Woodruff et al., 2011). Our observed concentrations of
lead, cadmium, and mercury are comparable or slightly lower than
those for women age 20–39 in the Canadian Health Measures Survey
(CHMS) (Health Canada, 2010), and are comparable to those found in
the NHANES (Woodruff et al., 2011). Our observed average arsenic
levels were comparable to those from a small study assessing metals
and glucose tolerance in a non-pregnant population (Serdar et al.,
2009), and somewhat lower than blood arsenic levels from a U.S.
study of arsenic exposure and glucose tolerance during pregnancy
(Ettinger et al., 2009). In comparing the levels of arsenic observed in
our study with those of women age 20–39 in the CHMS, the 10th,
25th and 50th percentiles were similar, while the 75th, 90th, and 95th
percentiles from theMIREC cohort were somewhat lower than the cor-
responding percentiles in the CHMS (Health Canada, 2010). Neverthe-
less, our highest observed arsenic concentrations were substantially
above the 95th percentile from the CHMS. In order to account for the
possible effects of these outliers, we conducted a sensitivity analysis in
which values more than three standard deviations from the arithmetic
mean (12 participants) were removed. The observed odds of GDM
were similar to the overall study group (highest quartile of arsenic:crude OR = 3.6 (95% CI 1.4–9.2); adjusted OR = 3.5 (95% CI 1.3–9.2)).
Similarly, the ORs for IGT and IGT/GDM were essentially unchanged.
New guidelines for GDMhave recently been adopted by the Interna-
tional Association of Diabetes and Pregnancy Study Groups and the Ca-
nadian Diabetes Association (Canadian Diabetes Association Clinical
Practice Guidelines Expert Committee et al., 2013; International
Association Diabetes and Pregnancy Study Groups Consensus Panel,
2010), but were not used in this study because they had not been
adopted when the MIREC subjects were being tested for GDM. Under
these new guidelines, a diagnosis of GDM will require only 1 abnormal
result from the OGTT. Thus, the new deﬁnition of GDMwill be similar to
the combined GDM/IGT category used in the current study. Although
we observed an increased risk of GDM/IGT with the highest quartile of
blood arsenic exposure, the odds ratio was attenuated from that ob-
served with GDM alone (i.e., not including IGT). If a gradient exists be-
tween the level of glucose intolerance and the risks associated with
chemical exposures, future studies evaluating the association between
chemical exposure and GDM (under the new criteria) may fail to detect
signiﬁcant associations.
An important limitation of our analysis is the use of a single urinary
measure for BPA and phthalates. As these chemicals have short elimina-
tion half-lives (Koch et al., 2005; Volkel et al., 2002), within-person var-
iability in urinary BPA concentrations (Fisher et al., 2014; Kuo et al.,
2013; Robledo et al., 2013) and phthalates (Fisher et al., 2014; Kuo
et al., 2013) has been reported to be low, with intraclass correlation co-
efﬁcients ranging from0.11 to 0.31 (Braun et al., 2011; Jusko et al., 2014;
Fisher et al., 2014; Meeker et al., 2013; Quiros-Alcala et al., 2013). How-
ever, as within-person BPA and exposure variability is unlikely to be re-
lated to our study outcomes, we expect any resulting bias would be
non-differential. Future studies incorporating multiple measurements
are needed to better illuminate variation in levels and effects of BPA
and phthalates across pregnancy. Although a critical exposure window
in gestation is not known, it is reassuring that the dates of urine sample
collection precededmeasurement of glucose tolerance for 1117 (99%) of
participants for whom data were available.
There were a substantial number of subjects for whom a GCT was
not performed andwhowere therefore excluded fromour analyses. No-
tably, current smokersweremore frequently excluded, whichmay have
biased our results towards the null, particularly for cadmium. However,
given the small magnitude of the differences between included and ex-
cluded participants, we do not expect that selection biaswould strongly
affect our ﬁndings. Our study has several notable strengths, including
the prospective nature of the study design,which overcomes the limita-
tions of the previous cross-sectional research, and individual-level ex-
posure measurement. We were also able to account for a rich variety
of potential confounding variables using the comprehensive question-
naire data and anthropometric measurements collected in the MIREC
study.5. Conclusions
Using a prospective cohort design, we evaluated the relationships
between phthalates, BPA and metals measured during the ﬁrst trimes-
ter of pregnancy with IGT and GDM based on published national guide-
lines. We did not ﬁnd evidence of associations between the new
emerging chemicals we examined (phthalates and BPA) and glucose
tolerance disorders in pregnancy, though our use of a single exposure
measurement for these chemicals constitutes a limitation.We observed
a strong association between elevated ﬁrst-trimester blood arsenic
levels and GDM, aswell as a signiﬁcant association between blood arse-
nic and GDM and IGT combined. These ﬁndings add to previous epide-
miologic research showing associations between arsenic and diabetes,
and are consistent with the other studies of arsenic exposure and glu-
cose tolerance disorders in pregnantwomen. Finally, we did not ﬁnd ev-
idence of an association between other metals and IGT or GDM.
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